Compare

Haleon plc/£HLN

1D1W1M3M6MYTD1Y5YMAX

About Haleon plc

Haleon plc is a consumer healthcare company that focuses on the development, manufacturing, and distribution of health products. The company operates in the healthcare industry, specifically targeting wellness and over-the-counter products. Haleon's portfolio includes well-known brands such as Sensodyne, Advil, and Centrum, which are aimed at providing solutions for oral health, pain relief, and dietary supplementation. Headquartered in the United Kingdom, the company maintains a global presence with a significant geographic footprint in numerous markets. Haleon's strategic positioning lies in its focus on scientifically backed consumer health products and a robust brand portfolio, which supports its competitive presence in the healthcare sector.
Ticker
£HLN
Sector
Health
Primary listing
LSE
Employees
24,535
Headquarters
Weybridge, United Kingdom
Website
www.haleon.com

Haleon plc Metrics

BasicAdvanced
£28B
17.48
£0.18
0.25
£0.07
2.31%

What the Analysts think about Haleon plc

Analyst ratings (Buy, Hold, Sell) for Haleon plc stock.
Analyst projections of the future price of Haleon plc stock.

Bulls say / Bears say

Oral Health remains Haleon’s standout growth engine: sales rose 8.8% in Q3, with Sensodyne and innovation supporting momentum. This offers a bright spot even as other categories weaken. (Haleon)
Haleon still expects high-single-digit adjusted operating profit growth for 2026 despite lowering its sales outlook. In the first half, adjusted operating profit rose 8.2% and free cash flow reached £769m, supporting a further £500m share buyback. (Haleon, Haleon)
North America and emerging markets show potential for a recovery: Q3 growth was 2.5% and 5.1% respectively, with high-teens growth in India. In the US, Haleon’s consumer-health market share had risen each month since February, Reuters reported. (Haleon, Reuters)
Haleon cut its 2026 organic revenue growth outlook to around 2.5% from 3–5% after Q3 growth came in below expectations. The setback includes a halt to imports of some Centrum products in China and a temporary revenue hit from changes to its Brazil sales model. (Haleon)
The weakness is not confined to one temporary disruption: Europe’s Q3 revenue fell 0.9%, while Respiratory Health declined 2.0% and VMS organic revenue slipped 0.5%. Persistent softness in these areas could make a return to faster growth difficult. (Haleon)
J.P. Morgan questioned whether Haleon can sustain its medium-term growth and margin targets, citing weak historical volume growth and market-share losses in OTC and vitamins, minerals and supplements. The bank also warned that further margin gains may require greater investment. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Haleon plc Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Haleon plc Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Haleon plc

AllEURGBPUSD
Funds
Fund name
Fund size
£HLN weighting
iShares MSCI Europe Health Care Sector€ESIH
€890M2.33%
iShares MSCI Europe Health Care Sector£ESIH
€890M2.33%
iShares STOXX Europe 600 Health Care€EXV4
€709M2.22%
HSBC MSCI Europe Islamic Screened$HIEU
€144M1.47%
HSBC MSCI Europe Islamic Screened£HIPS
€144M1.47%
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.